Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: Shield Therapeutics plc

Market Cap 69.45M 91.87M 80.1M 74.19M 130M 8.67B 131M 880M 341M 4.27B 345M 337M 14.82B P/E 2026 *
-295x
P/E 2027 * 8.81x
Enterprise Value 87.5M 116M 101M 93.47M 164M 10.92B 165M 1.11B 430M 5.38B 434M 425M 18.67B EV / Sales 2026 *
1.57x
EV / Sales 2027 * 1.07x
Free-Float
38.23%
Yield 2026 *
-
Yield 2027 * -
1 day+1.56%
Current month+9.24%
3 months-19.75%
6 months-42.22%
Current year-34.01%
1 week 6.3
Extreme 6.3
6.7
1 month 5.7
Extreme 5.7
6.7
Current year 5.7
Extreme 5.7
12.5
1 year 2.39
Extreme 2.39
12.5
3 years 1.06
Extreme 1.0625
12.85
5 years 1.06
Extreme 1.0625
61
10 years 1.06
Extreme 1.0625
202
Manager TitleAgeSince
Chief Executive Officer 64 24/07/2024
Investor Relations Contact - -
General Counsel - 01/08/2015
Director TitleAgeSince
Chairman 70 18/06/2020
Director/Board Member 68 01/02/2016
Director/Board Member 59 10/05/2021
Date Insider Type Main position Quantity % Market Cap.
14/10/25Free

Chief Executive Officer

1,547,262 0.1485%
13/02/25Buy

Chief Executive Officer

575,000 0.0552%
13/02/25Free

Chief Executive Officer

5,000,000 0.4800%
Change 5-day change 1-year change 3-year change Capi.($)
+1.56%0.00%+168.04%-3.85% 91.87M
+0.33%-0.36%+19.66%-21.92% 62.05B
+0.20%-9.17%+58.54%+194.67% 54.52B
-3.92%+37.40%+37.40%+37.40% 41.55B
+7.62%+8.19%-51.58%-58.97% 39.06B
-1.05%-1.73%+54.74%-33.09% 29.02B
+3.50%+28.15%+146.95%-48.51% 25.38B
-0.78%-9.50%+43.47%+59.06% 19.62B
+1.74%-0.39%-1.99%+126.64% 16.89B
-0.05%+0.23%+61.48%+104.74% 15.89B
Average +0.92%+2.50%+53.67%+35.62% 30.41B
Weighted average by Cap. +0.78%+1.72%+36.44%+37.07%

Financials

2026 *2027 *
Net sales 55.68M 73.65M 64.22M 59.48M 104M 6.95B 105M 706M 273M 3.42B 276M 271M 11.88B 75.12M 99.37M 86.64M 80.24M 141M 9.38B 142M 952M 369M 4.62B 373M 365M 16.03B
Net income -74.5K -98.55K -85.93K -79.58K -140K -9.3M -141K -944K -366K -4.58M -370K -362K -15.89M 7.86M 10.4M 9.07M 8.4M 14.74M 981M 14.83M 99.61M 38.61M 483M 39.03M 38.2M 1.68B
Net Debt 18.05M 23.88M 20.82M 19.28M 33.85M 2.25B 34.06M 229M 88.65M 1.11B 89.63M 87.7M 3.85B 10.95M 14.48M 12.63M 11.7M 20.54M 1.37B 20.66M 139M 53.78M 673M 54.37M 53.2M 2.34B
Logo Shield Therapeutics plc
Shield Therapeutics plc is a United Kingdom-based commercial-stage pharmaceutical company. The Company delivers differentiated specialty pharmaceuticals that address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company’s lead product, Accrufer/Feraccru, is broadly indicated for use in adults across multiple therapeutic categories. Ferric maltol is approved in the United States, European Union, the United Kingdom, Canada, Australia and Switzerland for the treatment of iron deficiency with or without anemia in adults. It also has an exclusive licence agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialization of ACCRUFeR/FeRACCRU in China, Hong Kong, Macau and Taiwan, with Korea Pharma Co., Ltd. for the Republic of Korea. The Company's subsidiaries include Phosphate Therapeutics Limited, Shield TX (Switzerland) AG, Shield Therapeutics Inc, and Shield TX (UK) Limited.
Employees
61
Date Price Change Volume
19/06/26 6.500 p +1.56% 981,222
18/06/26 6.400 p 0.00% 479,983
17/06/26 6.400 p 0.00% 1,049,175
16/06/26 6.400 p 0.00% 331,124
15/06/26 6.400 p -1.54% 1,292,122
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
0.0650GBP
Average target price
0.1667GBP
Spread / Average Target
+156.42%

Annual profits - Rate of surprise

LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!